The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma

Chest

Volumn 115, Issue 1, 1999, Pages 210-217

  Georgitis, John W ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Asthma guidelines; Asthma management; Inhaled corticosteroids

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; LEUKOTRIENE; MONTELUKAST; NEDOCROMIL; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON;

ASTHMA; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRY POWDER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0032905475     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.115.1.210     Document Type: Review

References (57)

1. 1 National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. NIH Publication No. 97-4051. Bethesda, MD: National Institutes of Health, 1997
2. 2 Dixon CMS, Barnes PJ. Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol 1989; 27:831-836
3. 3 Clark B. General pharmacology, pharmacokinetics, and toxicology of nedocromil sodium. J Allergy Clin Immunol 1993; 92(1, pt 2):200-202
4. 4 Alton EW, Norris AA. Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 1996; 98:102-106
5. 5 Juniper EF, Kline PA, Morris MM, et al. Airway constriction by isocapnic hyperventilation of cold, dry air: comparison of magnitude and duration of protection by nedocromil sodium and sodium cromoglycate. Clin Allergy 1987; 17:523-528
6. 6 de Benedictis FM, Tuteri G, Pazzelli P, et al. Cromolyn versus nedocromil: duration of action in exercise-induced asthma in children. J Allergy Clin Immunol 1995; 96:510-514
7. 7 Lal S, Dorow PD, Venho KK, et al. Nedocromil sodium is more effective than cromolyn sodium for the treatment of chronic reversible obstructive airway disease. Chest 1993; 104:438-447
8. 8 Svendsen UG, Jørgensen H. Inhaled nedocromil sodium as additional treatment to high-dose inhaled corticosteroids in the management of bronchial asthma. Eur Respir J 1991; 4:992-999
9. 9 O'Hickey SP, Rees PJ. High-dose nedocromil sodium as an addition to inhaled corticosteroids in the treatment of asthma. Respir Med 1994; 88:449-502
10. 10 Wong CS, Cooper S, Britton JR, et al. Steroid sparing effect of nedocromil sodium in asthmatic patients on high doses of inhaled steroids. Clin Exp Allergy 1993; 23:370-376
11. 11 Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med 1993; 87:227-228
12. 12 Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306:1034-1037
13. 13 Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488
14. 14 Faurschou P, Steffensen I, Jacques L. Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose steroids. Eur Respir J 1996; 9:1885-1890
15. 15 Kraemer R, Graf Bigler U, Casaulta Aebischer G, et al. Clinical and physiological improvement after inhalation of low-dose beclomethasone dipropionate and salbutamol in wheezy infants. Respiration 1997; 64:342-349
16. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-623
17. 17 Georgitis JW. Asthma therapy: what's new and is it necessarily better [editorial]? Chest 1997; 112:3-5
18. 18 Israel E, Cohn J, Dubé L, et al. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275:931-936
19. 19 Wechsler ME, Carpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279:455-457
20. 20 Knoell DL, Lucas J, Allen TN. Churg-Strauss syndrome associated with zafirlukast. Chest 1998; 114:332-334
21. 21 Wenzel SE. Asthma as an inflammatory disease. Ann Allergy 1994; 72:261-271
22. 22 Taylor IK, O'Shaughnessy, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991; 337:690-694
23. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90:193-201
24. 24 Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148(suppl): S1-S26
25. 25 Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145:669-674
26. 26 Duddridge M, Ward C, Hendrick DJ, et al. Changes in bronchoalveolar lavage inflammatory cells in asthmatic patients treated with high-dose inhaled beclomethasone dipropionate. Eur Respir J 1993; 6:489-497
27. 27 Rafferty P, Tucker LG, Frame MH, et al. Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisolone-sparing effects. Br J Dis Chest 1985; 79:244-250
28. 28 Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995; 332:868-875
29. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90:32-42
30. 30 Nathan RA, Nolop KB, Cuss FM, et al. A comparison of double-strength beclomethasone dipropionate (84 μg) MDI with beclomethasone dipropionate (42 μg) MDI in the treatment of asthma. Chest 1997; 112:34-39
31. 31 Högger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59:597-602
32. 32 Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97: 169-176
33. 33 Derendorf H, Hochhaus G, Möllmann H, et al. Receptor-based pharmacokinetic pharmacodynamic analysis ofcorticosteroids. J Clin Pharmacol 1993; 33:115-123
34. 34 Brattsand R, Thalen A, Roempke K, et al. Development of new glucocorticosteroids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982; 63(suppl):62-73
35. 35 Johansson S-A, Andersson K-E, Brattsand R, et al. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir Dis 1982; 63(suppl):74-82
36. 36 Würthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990; 11:381-394
37. 37 Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of inhaled corticosteroids. Am J Respir Crit Care Med 1996; 153:1739-1748
38. 38 Högger P, Bonsmann U, Rohdewald P. Efflux of glucocorticoids from human lung tissue to human plasma in vitro [abstract P1735]. Eur Respir J 1994; 7:382s
39. 39 Goldstein DE, König P. Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-adrenal axis function in children with asthma. Pediatrics 1983; 72:60-64
40. 40 Clark DJ, Grove A, Cargill RI, et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51:262-266
41. 41 Boe J, Bakke P, Rødølen T, et al. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J 1994; 7:2179-2184
42. 42 Grove A, Allam C, McFarlane LC, et al. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol 1994; 38:527-532
43. 43 Lönnebo A, Grahnén A, Jansson B, et al. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49:459-463
44. 44 Grahnen A, Eckernas SA, Brundin RM, et al. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994; 38:521-525
45. 45 Boorsma M, Andersson N, Larsson P, et al. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996; 9:1427-1432
46. 46 Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84(suppl A):25-29
47. 47 Högger P, Esmailpour N, Rabe K, et al. Distribution of inhaled fluticasone propionate between lung tissue and blood plasma in vivo [abstract P1530]. Eur Respir J 1995; 8:3035
48. 48 Francis RS. Long-term beclomethasone dipropionate aerosol therapy in juvenile asthma. Thorax 1976; 31:309-314
49. 49 Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986; 61:1049-1055
50. 50 Davies B. A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. Br J Clin Pharmacol 1993; 47:87-93
51. 51 Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics, 1997; 1004-1007, 1089-1092, 2175-2176
52. 52 Newhouse MT. Pulmonary drug targeting with aerosols. Am J Asthma Allergy Pediatr 1993; 7:23-34
53. 53 Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7:1839-1844
54. 54 Kemp JP, Furukawa CT, Bronsky EA, et al. Albuterol treatment for children with asthma: a comparison of inhaled powder and aerosol. J Allergy Clin Immunol 1989; 83:697-702
55. 55 Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of Turbuhaler. Arch Dis Child 1990; 65:308-310
56. 56 Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 119:169-177
57. 57 Meakin BJ, Cainey JM, Woodcock PM. Simulated "in-use" and "mis-use" aspects of the delivery of terbutaline sulphate from bricanyl Turbuhaler dry powder inhalers. Int J Pharm 1995; 119:103-108